Fig. 1.
Goodness-of-fit plots for the final population-pharmacokinetic model of risankizumab. a Population-predicted vs. observed risankizumab plasma concentrations; b individual-predicted vs. observed risankizumab plasma concentrations; c conditional weighted residuals vs. population-predicted concentrations; and d conditional weighted residuals vs. time after first dose